{"id":1425,"date":"1999-03-01T12:03:00","date_gmt":"1999-03-01T11:03:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/1999\/leserbriefe-nochmals-angioneurotisches-oedem-als-nebenwirkung-von-losartan"},"modified":"1999-03-01T12:03:00","modified_gmt":"1999-03-01T11:03:00","slug":"leserbriefe-nochmals-angioneurotisches-oedem-als-nebenwirkung-von-losartan","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/1999\/leserbriefe-nochmals-angioneurotisches-oedem-als-nebenwirkung-von-losartan","title":{"rendered":"Leserbriefe: Nochmals: Angioneurotisches \u00d6dem als Nebenwirkung von Losartan"},"content":{"rendered":"<p>Prof. Dr. H.W. aus W\u00fcrzburg schreibt: >> Das geh\u00e4ufte Vorkommen von Angio\u00f6demen nach Losartan (AMB 1998, 32, 96b) l\u00e4\u00dft aufhorchen, ebenso die Beobachtung, da\u00df in der angef\u00fchrten Originalarbeit (Arch. Int. Med. 1998, 158, 2063) Frauen h\u00e4ufiger als M\u00e4nner (11 vs. 2) betroffen waren. Ein gleiches Geschlechterverh\u00e4ltnis sei auch f\u00fcr ACE-Hemmer-assoziierte Angio\u00f6deme gefunden worden, wobei wohl [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Prof. Dr. H.W. aus W\u00fcrzburg schreibt: >> Das geh\u00e4ufte Vorkommen von Angio\u00f6demen nach Losartan (AMB 1998, 32, 96b) l\u00e4\u00dft aufhorchen, ebenso die Beobachtung, da\u00df in der angef\u00fchrten Originalarbeit (Arch. Int. Med. 1998, 158, 2063) Frauen h\u00e4ufiger als M\u00e4nner (11 vs. 2) betroffen waren. Ein gleiches Geschlechterverh\u00e4ltnis sei auch f\u00fcr ACE-Hemmer-assoziierte Angio\u00f6deme gefunden worden, wobei wohl [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[1733,1732,316,309,312,314,313,315,317,320,311,307,319,310,321,2503,306],"class_list":["post-1425","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-angioneurotisches-oedem","tag-angiooedem","tag-angiotensin-ii-antagonisten","tag-angiotensin-ii-blocker","tag-angiotensin-ii-inhibitoren","tag-angiotensin-ii-rezeptor-antagonisten","tag-angiotensin-ii-rezeptor-blocker","tag-angiotensin-ii-rezeptor-inhibitoren","tag-at-ii-antagonisten","tag-at-ii-blocker","tag-at-ii-inhibitoren","tag-at-ii-rezeptor-antagonisten","tag-at-ii-rezeptor-blocker","tag-at-ii-rezeptor-inhibitoren","tag-losartan","tag-quincke-oedem","tag-sartane"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1425","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=1425"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1425\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=1425"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=1425"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=1425"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}